AtaiBeckley Inc. Share Price & Technical Analysis
ATAI · $4.32 (-0.23%)
Healthcare / Biotechnology
$4.32
-0.23%
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder;…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
2% return in May, 11% avg return in past 3 year May month.
7% return in 2026, 30% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -10% | -3% | 0% | 17% | 2% | – | – | – | – | – | – | – | 7% |
| 25 | 7% | 13% | -18% | 7% | 53% | -12% | 58% | 15% | 20% | 9% | -33% | 8% | 129% |
| 24 | 29% | 6% | 5% | 0% | -16% | -19% | 15% | -13% | -8% | -8% | 64% | -28% | 27% |
| 23 | -33% | -6% | 6% | 0% | -5% | -6% | 17% | -29% | -13% | -8% | -17% | 27% | -66% |
| 22 | -31% | 4% | -11% | -16% | -7% | -10% | 8% | 15% | -27% | -12% | 9% | -23% | -99% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.45B
P/E ratio
—
52W high
$6.75
52W low
$1.91
Volume
49,65,460
Beta
1.60
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is AtaiBeckley Inc. share price today?
- AtaiBeckley Inc. (ATAI) last traded around $4.32 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ATAI have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ATAI. Download the app for real-time alerts.
- How can I analyze AtaiBeckley Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.